SCHEMBL16070213

SCHEMBL16070213

CNC(=O)c1cc(COc2cnc(Nc3ccc(CCN(C)C)cc3)nc2)c(F)c(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 7/20 0.40
▸ CCNT1 O60563 1/20 0.40
▸ CCNA2 P20248 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ CDK9 P50750 1/20 0.40
▸ FGFR3 P22607 4/20 0.39
▸ FGFR1 P11362 3/20 0.39
▸ FGFR4 P22455 3/20 0.39
▸ FGFR2 P21802 1/20 0.39
▸ KCNH2 Q12809 3/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ DRD2 P14416 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ DRD3 P35462 1/20 0.37
▸ MELK Q14680 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ NTRK1 P04629 1/20 0.37
▸ TYK2 P29597 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16069792 0.88 PTK2 (0.44) PTK2FGFR3FGFR1FGFR4FGFR2
SCHEMBL16069930 0.87 PTK2 (0.42) PTK2FGFR3FGFR1FGFR4FGFR2
SCHEMBL17469985 0.86 PTK2 (0.45) PTK2FGFR3FGFR1FGFR4FGFR2
SCHEMBL16070250 0.86 PTK2 (0.45) PTK2FGFR3FGFR1FGFR4FGFR2
SCHEMBL16070358 0.85 FGFR3 (0.47) PTK2FGFR3FGFR1FGFR4FGFR2
SCHEMBL16069790 0.83 PTK2 (0.42) PTK2FGFR3FGFR1FGFR4FGFR2
SCHEMBL16070506 0.83 FGFR3 (0.42) PTK2FGFR3FGFR1FGFR4FGFR2
SCHEMBL16070511 0.83 ABL1 (0.44) PTK2KDR
SCHEMBL16070248 0.83 FGFR1 (0.38) PTK2CCNT1CCNA2CDK2CDK9
SCHEMBL16069765 0.82 PTK2 (0.40) PTK2CDK2FGFR3FGFR1FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9701680-B2 Pyrimidine and pyridine compounds and their usage HUTCHISON MEDIPHARMA LIMITED (CN) 2017-07-11 — — US disclosed
US-20160024021-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE HUTCHISON MEDIPHARMA LIMITED (CN) 2016-01-28 — — US disclosed
WO-2014139465-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE HUTCHISON MEDIPHARMA LIMITED (CN) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024021-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE FGFR3, FGFR1, FGFR4 PTK2 1034/4885CCNT1 163/4885CCNA2 563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback